Acelity Announces Plans to File for IPO

Wound healing and regenerative medicine company Acelity (with its affiliate KCI) filed an S-1 on April 17th, the latest in a flurry of IPO activity (including the Silk Road Medical IPO earlier this month) in the medical technology space. The number of shares to be offered and pricing information has not been made public. J.P. Morgan, Goldman Sachs & Co. LLC and BofA Merrill Lynch are acting as joint book-running managers.

Acelity has been owned by private equity firm Apax Partners since July of 2013, when they purchased the company for $6.3 billion. They attempted to take the company public in 2015, but that S-1 was withdrawn. Acelity offers a suite of wound healing products, including novel negative-pressure wound therapy devices, dressings and tissue matrices.

In 2018, Acelity reported revenues of $1.5 billion, up from $1.3 billion the prior year.